RET and neoplasm: Lenvatinib is an oral, multitargeted TKI of VEGFR1-VEGFR3, RET, fibroblast growth factor receptors 1–4 (FGFR1-FGFR4), PDGFRα, and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis (33).